Key Highlights

  • Shares were down 11.92% to USD 1.70 in pre-market trading on November 3, 2026.
  • No company announcement dated November 2 or November 3, 2026 was identified.
  • A 50-to-1 share consolidation took effect on October 12, 2026.
  • Nasdaq confirmed minimum bid price compliance in writing on October 23, 2026.
  • A special meeting on December 2, 2026 will vote on a possible split of up to 50 for 1.

What moved Medicus Pharma in pre-market trading (down USD 0.2301, 11.92%)

Medicus Pharma (NASDAQ:MDCX) was down 11.92% to USD 1.70 in pre-market trading on November 3, 2026. The implied prior close from Monday, November 2, 2026 is about USD 1.93 (calculated).

No company press release or regulatory filing dated November 2 or November 3, 2026 was identified. The decline appears to be a continuation of Volatility after a 50-to-1 share consolidation, with only about 1.9 million shares outstanding.

Reverse split and a possible reversal

Medicus completed a 50-to-1 consolidation of its common shares on October 12, 2026, following Shareholder approval on June 3, 2026.

A company proxy statement now asks shareholders to approve a board-discretionary split of up to 50 post-split shares for each pre-split share, which the filing says could substantially reverse the consolidation. The board says it does not plan a ratio it expects would push the price below USD 1.00. The meeting is set for December 2, 2026, with a Record Date of October 28, 2026.

Business background and recent updates

Medicus Pharma is an Ontario-incorporated clinical-stage biotech. Its SkinJect program is a dissolvable microneedle patch that delivers doxorubicin to basal cell carcinoma lesions, and it also holds Teverelix, a long-acting GnRH antagonist for advanced prostate cancer and acute urinary retention.

On September 10, 2026, the company said its final Phase 2 clinical study report identified a 200 microgram patch as the lead dose. On September 2, 2026 it entered an agreement with Pfizer (NYSE:PFE) covering CD228V, an early clinical-stage antibody-drug conjugate. Under the 8-K, Medicus paid a USD 12.0 million upfront payment, owes a further USD 15.0 million on the first anniversary, with Pfizer eligible for milestones exceeding USD 1.0 billion.

Balance sheet and listing risks

Nasdaq confirmed compliance with the USD 1.00 minimum bid price on October 23, 2026, after a qualifying period from October 12 to October 23, 2026. The company cautioned that continued compliance is not guaranteed.

Operating cash outflow for 2025 was about USD 22.8 million according to market data, and two secured promissory notes from a USD 22 million Facility mature on November 28, 2027. With a share price this low and a small share count, the stock carries volatility, Liquidity and dilution risk.

What to watch next

The December 2, 2026 special meeting is the next scheduled event, and proxy materials are expected to be mailed around November 10, 2026.

Updates on SkinJect enrollment, the CD228V program and the company's cash position would also be relevant. Absent new disclosure, price swings may reflect trading dynamics after the consolidation.